[Clinical investigation of combined therapy (cefotiam, sulbenicillin and cefsulodin) against infections complicated by acute leukemia].
Prophylaxis effect and clinical therapy of combination use of cefotiam (CTM), sulbenicillin (SBPC) and cefsulodin (CFS) have been investigated, and the results were as follows. 1. Prophylaxis effect of CTM-SBPC combination therapy was very useful. CTM-SBPC combination therapy was performed to patients who are at high risk for infectious complications. Prophylaxis effect of CTM-SBPC was judged by fever over 38 degrees C, and was better than usual antibiotic treatment. 2. CTM-SPBC-CFS combination therapy was performed against severe infections during early remission, and the overall effectiveness rate was 83.3% (5/6). 3. No remarkable side effect was observed in this investigation.
D000208:Acute Disease; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015310:Cefotiam; D002441:Cefsulodin; D002511:Cephalosporins / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007938:Leukemia / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010400:Penicillin G / Q000031:analogs & derivatives*; D013408:Sulbenicillin / Q000008:administration & dosage*
D002511:Cephalosporins; D015310:Cefotiam; D002439:Cefotaxime; D002441:Cefsulodin; D013408:Sulbenicillin; D010400:Penicillin G